Ru et al. administered α-MSH twice a day to the ocular surface in a dry-eye model and showed that α-MSH at various doses improved tear secretion, enhanced tear film stability, preserved corneal integrity, and suppressed the overexpression of proinflammatory factors TNF-α, IL-1β, and IFN-γ on the ocular surface [8]. The gene discussed is STAMBP; the disease is dry eye syndrome.